68

Shanghai Rightongene Biotechnology Co. Ltd. A

688217 · SHG · Healthcare / Biotechnology

20.79CNY-0.71 (-3.30%)

Price History

Full chart

Market Stats

Previous Close21.50
Open21.15
Day Range20.64 – 21.67
52-Week Range17.81 – 33.27
Volume825.16K
Market Cap1.43B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.19
Dividend Yield0.66%
Beta0.39
50-Day Avg23.56
200-Day Avg26.55

About

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addition, it provides third-party medical testing services to various medical institutions, pharmaceutical companies, and individual patients, as well as gene testing research services to research hospitals, pharmaceutical companies, research institutions, and other third-party testing organizations. Shanghai Rightongene Biotechnology Co., Ltd. was founded in 2012 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Shangxian Gao
  • Employees327
  • HeadquartersNo. 147, Lane 1817, Shanghai, China, 201403, China
  • Websitehttps://www.rightongene.com

Leadership

  • Mr. Shangxian GaoChairman & GM · b. 1957
  • Mr. Zhong He KeR&D Director and Director · b. 1986
  • Ms. Chengli ZhangDeputy General Manager · b. 1958
  • Ms. Liqun XieDeputy General Manager · b. 1964

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue255.48M284.93M290.95M424.30M258.21M242.31M177.26M
Growth (%)-+11.53%+2.11%+45.83%-39.14%-6.16%-26.84%
Cost of Revenue49.61M80.23M78.24M166.32M69.17M61.72M43.64M
Gross Profit205.87M204.70M212.71M257.97M189.04M180.59M133.62M
Gross Margin80.58%71.84%73.11%60.80%73.21%74.53%75.38%
Operating Expense165.90M159.66M178.51M171.67M188.69M189.84M144.62M
Operating Income39.97M45.04M34.20M86.30M352.27K-9.26M-11.00M
Operating Margin15.64%15.81%11.76%20.34%0.14%-3.82%-6.20%
EBITDA57.08M68.54M80.46M107.76M35.83M18.08M-10.62M
EBITDA Margin22.34%24.06%27.65%25.40%13.87%7.46%-5.99%
Net Income35.95M38.71M47.33M40.47M7.93M-15.76M-50.38M
Net Income Margin14.07%13.59%16.27%9.54%3.07%-6.51%-28.42%
R&D67.01M74.36M68.64M64.43M69.80M62.47M53.00M
R&D as % of Total Revenue26.23%26.10%23.59%15.18%27.03%25.78%29.90%
Interest Expense181.31K61.04K491.82K549.81K828.48K884.67K192.70K
Interest Expense % of Total Revenue0.07%0.02%0.17%0.13%0.32%0.37%0.11%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets655.81M722.85M947.53M1.08B1.04B985.70M885.39M
Total Liabilities47.84M61.07M50.87M112.45M76.48M65.06M39.17M
Total Equity607.97M646.69M888.81M936.90M945.78M909.26M844.88M
Cash128.21M142.02M123.36M203.85M161.68M139.15M104.96M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow11.68M70.11M77.97M73.07M45.10M59.98M45.55M
Capital Expenditure53.83M52.14M95.60M106.57M109.09M39.41M26.76M
Free Cash Flow-42.15M17.97M-17.63M-33.50M-64.00M20.57M18.79M
Dividends Paid--19.55K11.04K10.40M619.88K9.50M
FCF to OCF-360.82%25.63%-22.61%-45.84%-141.91%34.29%41.24%
Dividend Paid to FCF---0.11%-0.03%-16.24%3.01%50.59%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Apr 28, 2022Aug 24, 2022Oct 26, 2022Feb 27, 2023Apr 27, 2023
EPS Estimate--------
EPS Actual0.150.320.08-0.040.420.280.070.02
Surprise--------
Timing---Pre-marketPre-marketAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap1.43B
Enterprise Value1.21B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.14
Price / Book1.73
EPS-1.19
Book Value15.09
Revenue (TTM)156.77M
Gross Profit (TTM)114.47M
EBITDA-14.50M
Profit Margin-42.27%
Operating Margin-7.63%
Return on Equity-8.81%
Return on Assets-3.09%
Shares Outstanding55.86M
Shares Float33.06M
Beta0.39
Dividend Yield0.66%
Dividend Rate0.17
Payout Ratio0.00%

Dividends

20251×
0.17Oct 24, 2025
20231×
0.18Nov 30, 2023